Biosimilars in Immunology

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Europe leads the way for immunology biosimilars in the 7MM, and India is at the forefront in the emerging markets. In terms of immunology biosimilar penetration, the 5EU and India demonstrate the highest favorability towards uptake of biosimilars.
Japan and South Korea have an intermediate biosimilar penetration index, while the US market is the least favorable towards biosimilars. Pricing is a key issue for expensive-to-develop biosimilars entering an increasingly crowded autoimmune disease market.Biosimilars are intended to relieve healthcare-associated cost burden; however, the economic effects of incorporating them into clinical practice are unclear, due to increased time and staff costs required for switching patients onto biosimilars.
Pricing can be a differentiating strategy among different biosimilars and larger discounts over originator brands can boost greater uptake of specific biosimilars. Quotas dictate prescribing patterns in the 5EU; however, physicians show concern about switching to a biosimilar from the originator brand. The majority of KOLs interviewed by GlobalData indicated that they used biosimilars mostly for new patients. KOLs also cited reluctance to switch existing patients to biosimilars, highlighting that they did not want to change a biologic treatment that was working for the patient.
Other reasons against switching included lack of incentives for physicians, lack of switching data, and nocebo effects.Biogen, Sandoz, Pfizer, and Amgen are dominating the immunology biosimilars field. The immunology biosimilars space is dominated in developed markets by established brand names, including Biogen, Sandoz, Pfizer, and Amgen.
In India and South Korea, major biosimilar players include Celltrion, Cipla, and Zydus Cadila.

Scope

Components of the report include:

Introduction to Biosimilars in Immunology – Defining biosimilars in immunology and discussing the history of drugs approved across the 9MM.

Assessment of Marketed and Pipeline Products – An overview of biosimilar products on the market and drugs currently in clinical development.

Regulatory Strategies – Overview of biosimilar regulatory strategies by country.

Market Dynamics – Overview of biosimilar market dynamics by country.

Focus Indications and Market Potential – In-depth assessment of biosimilars in major autoimmune indications, market potential as well as drivers and barriers to uptake.

Key Players – In-depth assessment of key players in the space across the 9MM

Key Clinical and Commercial Concepts – An examination of key clinical and commercial concepts in the biosimilars in immunology space, based on KOL and payer insights. Pricing and reimbursement infrastructure and challenges are examined.

Future Opportunities – Overview of future strategies recommended by KOLs and payers for boosting biosimilar uptake is discussed.

Abbvie
Amgen
Alexion
Johnson & Johnson
Novartis
Bristol Myers Squib
Takeda
Sanofi
Roche
Pfizer
UCB
Biogen
Sandoz
Hetero Pharmaceuticals
Mylan
Biocon
Cipla
Zydus Cadila
Fresenius Kabi
Samsung Bioepsis
Intas
Fujifilm
Merck
Mochida
Lupin
Celltrion
YDr. Reddy's
Torrent Pharma

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1 Related Reports

1.2 Upcoming Reports

1.3 Abbreviations

2. Executive Summary

2.1 Key Findings

2.2 KOL and Payer Insights

3. Introduction

3.1 What Is a Biosimilar?

3.2 Timeline of Immunology Biosimilar Development

3.3 Marketed and Pipeline Immunology Biosimilars in the 9MM

4. Biosimilar Regulatory Pathways Across Geographies

4.1 Biosimilar Regulatory Pathways

4.2 US Biosimilar Regulatory Pathway

4.3 EU Biosimilar Regulatory Pathway

4.4 Japan Biosimilar Regulatory Pathway

4.5 South Korea Biosimilar Regulatory Pathway

4.6 India Biosimilar Regulatory Pathway

5. Biosimilar Country-Specific Dynamics, 9MM

5.1 Biosimilar Country-Specific Dynamics, 9MM

5.2 US Biosimilar Market Potential

5.3 5EU Biosimilar Market Potential

5.4 Japan Biosimilar Market Potential

5.5 South Korea Biosimilar Market Potential

5.6 India Biosimilar Market Potential

6. Important Indications in Immunology

6.1 Biologic Use in Immunology

6.2 Rheumatoid Arthritis

6.3 Psoriatic Arthritis

6.4 Axial Spondyloarthritis

6.5 Ulcerative Colitis

6.6 Crohn’s Disease

6.7 Plaque Psoriasis

7. Major Players

7.1 Importance of Manufacturer Reputation

7.2 Sandoz

7.3 Celltrion

7.4 Amgen

7.5 Mylan and Biocon

7.6 Pfizer

7.7 Biogen

8. Biosimilars – Key Clinical and Commercial Concepts

8.1 Cost Savings and Market Access

8.2 Patient Type

8.3 Prescription Quotas

8.4 Biosimilarity and Interchangeability

8.5 Brand Preference

8.6 Extrapolation of Data

9. Opportunities for Biosimilar Manufacturers

9.1 Strategies for Increasing Uptake of Biosimilars

9.2 Differentiation by Pricing

9.3 Differentiation by Innovation

10. Appendix

10.1 Primary Research

10.2 Sources

10.3 About the Authors

10.4 About GlobalData

10.5 Contact Us

10.6 Disclaimer

Frequently asked questions

Biosimilars in Immunology thematic reports
Currency USD
$995

Can be used by individual purchaser only

$1,995

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Biosimilars in Immunology was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Biosimilars in Immunology in real time.

  • Access a live Biosimilars in Immunology dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.